Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

R60

—

84efa2ae-c65a-5fde-ad0f-84537abb8e31

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
overall_survival_months
10
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.530
  • INFLAMMATORY_RESPONSE+0.510
  • IL6_JAK_STAT3_SIGNALING+0.500
  • ANGIOGENESIS+0.480
  • INTERFERON_GAMMA_RESPONSE+0.450
  • INTERFERON_ALPHA_RESPONSE+0.440
  • ALLOGRAFT_REJECTION+0.430
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
  • P53_PATHWAY+0.360
  • IL2_STAT5_SIGNALING+0.350

Top 10 suppressed

  • E2F_TARGETS-0.570
  • G2M_CHECKPOINT-0.540
  • PROTEIN_SECRETION-0.480
  • MYC_TARGETS_V1-0.440
  • MITOTIC_SPINDLE-0.380
  • SPERMATOGENESIS-0.340
  • MTORC1_SIGNALING-0.310
  • UNFOLDED_PROTEIN_RESPONSE-0.300
  • FATTY_ACID_METABOLISM-0.250
  • PEROXISOME-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-A2-A0CO-01A-13R-A22K-07
breast-umap@18
—A0.921
2R52
bladder-landscape@3
——0.919
3TCGA-AC-A2FE-01A-11R-A19W-07
breast-umap@18
—A0.915
4R304
bladder-landscape@3
——0.913
5BS_Z28VKGNS
brain-umap@2
Neurofibroma—0.910
620120155.TNBC
breast-umap@18
—D0.910
7SRR35579837
breast-umap@18
—D0.901
8R83
bladder-landscape@3
——0.901
9AUR-AER2-TTM3-A-1-1-R-A742-41
breast-umap@18
—D0.901
10MDT-AP-1125
medullo-epn-umap@date-based
MedMedulloblastoma0.899

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.530Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.510Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
ANGIOGENESIS0.480Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.450Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.440Inavolisib— uncovered
ALLOGRAFT_REJECTION0.430Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.430Inavolisib— uncovered
P53_PATHWAY0.360Idelalisib— uncovered
IL2_STAT5_SIGNALING0.350Idelalisib— uncovered
APICAL_JUNCTION0.330Inavolisib— uncovered
TGF_BETA_SIGNALING0.320Inavolisib— uncovered
APOPTOSIS0.310Idelalisib— uncovered
KRAS_SIGNALING_UP0.280Inavolisib— uncovered
COAGULATION0.270Binimetinib— uncovered
COMPLEMENT0.250Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.250Inavolisib— uncovered
HEDGEHOG_SIGNALING0.230Inavolisib— uncovered
MYOGENESIS0.230Inavolisib— uncovered
KRAS_SIGNALING_DN0.210Remibrutinib— uncovered